TrialPediatric nephrology (Berlin, Germany)2024

Estimating risk of rapid disease progression in pediatric patients with autosomal dominant polycystic kidney disease: a randomized trial of tolvaptan.

Djalila Mekahli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.